Skip to main content
Journal cover image

Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting.

Publication ,  Journal Article
Arroz, M; Came, N; Lin, P; Chen, W; Yuan, C; Lagoo, A; Monreal, M; de Tute, R; Vergilio, J-A; Rawstron, AC; Paiva, B
Published in: Cytometry B Clin Cytom
January 2016

BACKGROUND: Major heterogeneity between laboratories in flow cytometry (FC) minimal residual disease (MRD) testing in multiple myeloma (MM) must be overcome. Cytometry societies such as the International Clinical Cytometry Society and the European Society for Clinical Cell Analysis recognize a strong need to establish minimally acceptable requirements and recommendations to perform such complex testing. METHODS: A group of 11 flow cytometrists currently performing FC testing in MM using different instrumentation, panel designs (≥ 6-color) and analysis software compared the procedures between their respective laboratories and reviewed the literature to propose a consensus guideline on flow-MRD analysis and reporting in MM. RESULTS/CONCLUSION: Consensus guidelines support i) the use of minimum of five initial gating parameters (CD38, CD138, CD45, forward, and sideward light scatter) within the same aliquot for accurate identification of the total plasma cell compartment; ii) the analysis of potentially aberrant phenotypic markers and to report the antigen expression pattern on neoplastic plasma cells as being reduced, normal or increased, when compared to a normal reference plasma cell immunophenotype (obtained using the same instrument and parameters); and iii) the percentage of total bone marrow plasma cells plus the percentages of both normal and neoplastic plasma cells within the total bone marrow plasma cell compartment, and over total bone marrow cells. Consensus guidelines on minimal current and future MRD analyses should target a lower limit of detection of 0.001%, and ideally a limit of quantification of 0.001%, which requires at least 3 × 10(6) and 5 × 10(6) bone marrow cells to be measured, respectively.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Cytometry B Clin Cytom

DOI

EISSN

1552-4957

Publication Date

January 2016

Volume

90

Issue

1

Start / End Page

31 / 39

Location

United States

Related Subject Headings

  • Software
  • Research Design
  • Remission Induction
  • Prognosis
  • Plasma Cells
  • Neoplasm, Residual
  • Multiple Myeloma
  • Limit of Detection
  • Immunophenotyping
  • Immunology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Arroz, M., Came, N., Lin, P., Chen, W., Yuan, C., Lagoo, A., … Paiva, B. (2016). Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting. Cytometry B Clin Cytom, 90(1), 31–39. https://doi.org/10.1002/cyto.b.21228
Arroz, Maria, Neil Came, Pei Lin, Weina Chen, Constance Yuan, Anand Lagoo, Mariela Monreal, et al. “Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting.Cytometry B Clin Cytom 90, no. 1 (January 2016): 31–39. https://doi.org/10.1002/cyto.b.21228.
Arroz M, Came N, Lin P, Chen W, Yuan C, Lagoo A, et al. Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting. Cytometry B Clin Cytom. 2016 Jan;90(1):31–9.
Arroz, Maria, et al. “Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting.Cytometry B Clin Cytom, vol. 90, no. 1, Jan. 2016, pp. 31–39. Pubmed, doi:10.1002/cyto.b.21228.
Arroz M, Came N, Lin P, Chen W, Yuan C, Lagoo A, Monreal M, de Tute R, Vergilio J-A, Rawstron AC, Paiva B. Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting. Cytometry B Clin Cytom. 2016 Jan;90(1):31–39.
Journal cover image

Published In

Cytometry B Clin Cytom

DOI

EISSN

1552-4957

Publication Date

January 2016

Volume

90

Issue

1

Start / End Page

31 / 39

Location

United States

Related Subject Headings

  • Software
  • Research Design
  • Remission Induction
  • Prognosis
  • Plasma Cells
  • Neoplasm, Residual
  • Multiple Myeloma
  • Limit of Detection
  • Immunophenotyping
  • Immunology